Boston Scientific Corporation agreed to acquire Penumbra, Inc. Thursday morning. This will expand Boston Scientific’s network of novel medical technologies. “Penumbra is a well-established company with an experienced, high-performing team and this acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space," said Mike Mahoney, MBA, chairman and chief executive officer, Boston Scientific, in a Boston Scientific press release. Cardiovascular disease (CVD) is the number one cause of death worldwide. Penumbra and Boston Scientific have addressed this critical issue by developing innovative devices for the treatment and management of CVD. Penumbra’s portfolio includes several technologies that address complicated cardiovascular diseases, such as pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, acute myocardial infarction and aneurysms. Penumbra has led the world in thrombectomy devices, including the unique Lightning Bolt® and Lightning Flash® computer assisted vacuum thrombectomy (CAVT™) systems. The acquisition will be a cash and stock transaction between the two companies and it will be finalized sometime in 2026. Image Credit: Piai – stock.adobe.com